ImmunityBio, Inc. (NASDAQ:IBRX) Shares Acquired by Woodline Partners LP

Woodline Partners LP increased its position in ImmunityBio, Inc. (NASDAQ:IBRX - Free Report) by 682.7% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 3,442,440 shares of the company's stock after buying an additional 3,002,622 shares during the period. Woodline Partners LP owned about 0.49% of ImmunityBio worth $8,813,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also made changes to their positions in IBRX. Stephens Inc. AR acquired a new stake in ImmunityBio in the 4th quarter worth about $26,000. Cibc World Markets Corp purchased a new position in ImmunityBio during the fourth quarter worth approximately $35,000. Maia Wealth LLC acquired a new position in shares of ImmunityBio in the 4th quarter valued at $37,000. Schechter Investment Advisors LLC purchased a new stake in shares of ImmunityBio during the 4th quarter valued at $38,000. Finally, Ameriprise Financial Inc. acquired a new stake in shares of ImmunityBio during the 4th quarter worth $38,000. Hedge funds and other institutional investors own 8.58% of the company's stock.

ImmunityBio Stock Performance

ImmunityBio stock traded up $0.05 during trading on Tuesday, reaching $2.58. 6,204,609 shares of the company's stock were exchanged, compared to its average volume of 5,585,976. ImmunityBio, Inc. has a 52-week low of $1.83 and a 52-week high of $7.63. The firm has a market cap of $2.27 billion, a price-to-earnings ratio of -2.77 and a beta of 0.33. The company's 50-day moving average is $2.62 and its two-hundred day moving average is $3.16.

ImmunityBio (NASDAQ:IBRX - Get Free Report) last posted its earnings results on Monday, May 12th. The company reported ($0.15) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.12) by ($0.03). The firm had revenue of $16.52 million during the quarter, compared to analyst estimates of $17.50 million. Analysts anticipate that ImmunityBio, Inc. will post -0.92 EPS for the current year.

Analyst Ratings Changes

A number of research analysts recently weighed in on IBRX shares. Piper Sandler upgraded ImmunityBio from a "neutral" rating to an "overweight" rating and lifted their target price for the company from $4.25 to $5.00 in a report on Tuesday, May 20th. D. Boral Capital restated a "buy" rating and issued a $30.00 price objective on shares of ImmunityBio in a report on Monday, May 12th. Finally, HC Wainwright reiterated a "buy" rating and set a $8.00 target price on shares of ImmunityBio in a report on Monday, May 12th. Four research analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. According to MarketBeat, the stock has an average rating of "Buy" and a consensus target price of $12.25.

ImmunityBio Profile

ImmunityBio, Inc, a clinical-stage biotechnology company, engages in developing therapies and vaccines that bolster the natural immune system to defeat cancers and infectious diseases. Its platforms for the development of biologic product candidates include antibody-cytokine fusion proteins; DNA, RNA, and recombinant protein vaccines; and cell therapies.